Aptevo Therapeutics (APVO) SEC Filings: History & Chart

Aptevo Therapeutics Inc.(APVO)

Biotechnology · Seattle, WA

$1.86+0.06 (+3.33%)

Delayed quote: Oct 6, 2026, 9:39 AM EDT

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.

Seattle, WA

33 employees

www.aptevotherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jeffrey G. Lamothe

View full financials

Form	Filing Date	Accepted	Document
S-8	Sep 25, 2026	Sep 25, 2026	View filing
8-K	Sep 24, 2026	Sep 24, 2026	View filing
8-K	Sep 23, 2026	Sep 23, 2026	View filing
424B4	Sep 3, 2026	Sep 3, 2026	View filing
8-K	Sep 3, 2026	Sep 3, 2026	View filing
EFFECT	Sep 2, 2026	Sep 3, 2026	View filing
DEF 14A	Aug 31, 2026	Aug 31, 2026	View filing
D	Aug 26, 2026	Aug 26, 2026	View filing
PRE 14A	Aug 21, 2026	Aug 21, 2026	View filing
S-1	Aug 21, 2026	Aug 21, 2026	View filing
8-K	Aug 21, 2026	Aug 21, 2026	View filing
SC 13G/A	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
4	Aug 10, 2026	Aug 10, 2026	View filing
DEF 14A	Jul 31, 2026	Jul 31, 2026	View filing
ARS	Jul 31, 2026	Jul 31, 2026	View filing
8-K	Jul 27, 2026	Jul 27, 2026	View filing
S-8	Jul 24, 2026	Jul 24, 2026	View filing
8-K	Jun 30, 2026	Jun 30, 2026	View filing

SEC Filings

Recent Filings